• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
M et P Pharma AG - Product Pipeline Review - Q1 2011 Product Image

M et P Pharma AG - Product Pipeline Review - Q1 2011

  • ID: 1821610
  • May 2011
  • 25 pages
  • Global Markets Direct

M et P Pharma AG – Product Pipeline Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “M et P Pharma AG - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- M et P Pharma AG - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of M et P Pharma AG human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
M et P Pharma AG Snapshot
M et P Pharma AG Overview
Key Information
Key Facts
M et P Pharma AG – Research and Development Overview
Key Therapeutic Areas
M et P Pharma AG – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
M et P Pharma AG – Pipeline Products Glance
M et P Pharma AG Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
M et P Pharma AG–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
M et P Pharma AG – Drug Profiles
Nasobol
Product Description
Mechanism of Action
R&D Progress
DopaMat
Product Description
Mechanism of Action
R&D Progress
Noseafix
Product Description
Mechanism of Action
R&D Progress
ProgestoMat
Product Description
Mechanism of Action
R&D Progress
PregnenoMat
Product Description
Mechanism of Action
R&D Progress
M et P Pharma AG – Pipeline Analysis
M et P Pharma AG – Pipeline Products by Therapeutic Class
M et P Pharma AG - Pipeline Products By Target
M et P Pharma AG – Pipeline Products by Route of Administration
M et P Pharma AG – Pipeline Products by Molecule Type
M et P Pharma AG – Locations And Subsidiaries
Head Office
Financial Deals Landscape
M et P Pharma AG, Deals Summary, 2004 to 2011
M et P Pharma AG Detailed Deal Summary
Licensing Agreements
Urigen Pharmaceutical Enters Into Licensing Agreement With M et P Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
M et P Pharma AG – Pipeline by Therapy Area and Indication, 2011
M et P Pharma AG – Pipeline by Stage of Development, 2011
M et P Pharma AG – Monotherapy Products in Pipeline, 2011
M et P Pharma AG - Phase II, 2011
M et P Pharma AG - Phase I, 2011
M et P Pharma AG - Pipeline By Therapeutic Class, 2011
M et P Pharma AG - Pipeline By Target, 2011
M et P Pharma AG – Pipeline By Route of Administration, 2011
M et P Pharma AG – Pipeline By Molecule Type, 2011
M et P Pharma AG, Deals Summary, 2004 to 2011

List of Figures
M et P Pharma AG – Pipeline by Therapy Area and Indication, 2011
M et P Pharma AG – Pipeline by Stage of Development, 2011
M et P Pharma AG – Monotherapy Products in Pipeline, 2011
M et P Pharma AG – Pipeline By Therapeutic Class, 2011
M et P Pharma AG - Pipeline By Target, 2011
M et P Pharma AG – Pipeline By Molecule Type, 2011

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos